* Says announced long-term safety and efficacy results from
pivotal phase 3 Persist-1 trial
The post BRIEF-CTi Biopharma says Persist-1 phase 3 trial met its primary endpoint appeared first on NASDAQ.
BRIEF-CTi Biopharma says Persist-1 phase 3 trial met its primary endpoint
